Fast Market Research

Market Report, "Alzheimer's Disease - Pipeline Review, H2 2013", Published

New Pharmaceuticals market report from Global Markets Direct: "Alzheimer's Disease - Pipeline Review, H2 2013"


Boston, MA -- (SBWIRE) -- 09/27/2013 -- Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. Alzheimer's Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

View Full Report Details and Table of Contents

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Alzheimer's Disease.
- A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to Get This Report

- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., OXIS International, Inc., Shionogi & Co., Ltd., NsGene A/S, Amgen Inc., Sanofi-Aventis, AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Genentech, Inc., MedImmune LLC, Merck & Co., Inc., United Biomedical, Inc., Taisho Pharmaceutical Co., Ltd., Euroscreen S.A., Applied NeuroSolutions, Inc., ExonHit Therapeutics SA, Plexxikon Inc., Avineuro Pharmaceuticals, Inc., Panacea Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novartis AG, Isotechnika Pharma Inc., Samyang Corporation, Aphios Corporation, Alzhyme Ltd., EnVivo Pharmaceuticals, Astellas Pharma Inc., Chiesi Farmaceutici SpA, Daewoong Pharmaceutical Co., Ltd., Eisai Co., Ltd., Elan Corporation, plc, H Lundbeck A/S, Jeil Pharmaceutical Co., Ltd., Laboratoires Pierre Fabre SA, Les Laboratoires Servier, Octapharma AG, Orion Corporation, Pain Therapeutics, Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited, Toyama Chemical Co. Ltd, VIVUS, Inc., Hadasit Medical Research Services & Development Ltd, Addex Pharmaceuticals, Evotec Aktiengesellschaft, Anavex Life Sciences Corp., Neuralstem, Inc., Amicus Therapeutics, Inc., Genfit, AVANIR Pharmaceuticals, BELLUS Health Inc, Bionomics Limited, ReGenX Biosciences, LLC, Nymox Pharmaceutical Corporation, Osta Biotechnologies Inc., Paladin Labs Inc., Cortex Pharmaceuticals, Inc., Critical Outcome Technologies Inc., ACADIA Pharmaceuticals Inc., ProteoTech, Inc., Prana Biotechnology Limited, Lipoxen PLC, Biotie Therapies Corp., Transition Therapeutics Inc., Neurim Pharmaceuticals (1991) Ltd., Theravance, Inc., Resverlogix Corp., Suven Life Sciences Ltd., MediPost Co., Ltd., Summit Corporation plc, CrystalGenomics, Inc., Newron Pharmaceuticals S.p.A., Mithridion, Inc., Teikoku Pharma USA, Inc., Labtec GmbH, Xel Pharmaceuticals, Inc., Oryzon, TauRx Therapeutics Ltd, Ceregene, Inc., CoMentis, Inc., AC Immune SA, Humanetics Corporation, Accera, Inc., Sonexa Therapeutics, Inc., D-Pharm Ltd., Functional Genetics, Inc., StemCells, Inc., Proteome Sciences Plc, Upsher-Smith Laboratories, Inc., Probiodrug AG, Snowdon Inc., Domain Therapeutics, Pharmagenesis, Inc., reMYND, Acumen Pharmaceuticals, Inc., Wellstat Therapeutics Corporation, Celon Pharma Sp. z o.o., ALSP, Inc., IMMD Inc., CoLucid Pharmaceuticals, Inc., Metabolic Solutions Development Co., Hawthorn Pharmaceuticals, Inc., Cognition Therapeutics, Inc., BioArctic Neuroscience AB, Vaxin, Inc., Affichem, QR Pharma, Inc., NeuroNascent, Inc., Siena Biotech S.p.A., Virobay Inc., SeneXta Therapeutics SA, KineMed, Inc., ManRos Therapeutics, Intellect Neurosciences, Inc., Transtech Pharma, Inc., Xencor, Inc., Adeona Pharmaceuticals, Inc., Intra-Cellular Therapies, Inc., Stemedica Cell Technologies, Inc., Targacept, Inc., AB Science, Vitae Pharmaceuticals, Inc., Tautatis Incorporated, Lipopharma, Medisyn Technologies, Inc., TheraCarb Inc., VIB, PALUMED S.A., Proteostasis Therapeutics, Inc., Medestea Research & Production S.p.A., M's Science Corporation, NasVax Ltd., BrainCells Inc., Stelic Institute & Co., EndoCeutics, Inc., Pharnext SAS, PharmatrophiX, Inc., TREVENTIS Corporation, Ascenion GmbH, Phenomenome Discoveries, Inc., Satori Pharmaceuticals Inc., Inserm Transfert SA, Sinil Pharma Ltd., Heptares Therapeutics Ltd., Signum Biosciences, Inc., Neuraltus Pharmaceuticals, Inc., Femta Pharmaceuticals, Inc., ArmaGen Technologies, Inc., B&C Biopharm, Axon Neuroscience GmbH, RNL BIO Co., Ltd., Clera Inc., BioChromix Pharma AB, NAL Pharmaceuticals Ltd., Laila Pharmaceuticals Pvt. Ltd., Serometrix, LLC, Archer Pharmaceuticals, Inc., Varinel, Inc., Cognosci, Inc., Reviva Pharmaceuticals Inc., VLP Biotech, Inc., RaQualia Pharma Inc., Naurex, Inc., PharmaNeuroBoost N.V., America Stem Cell, Inc.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Crohn's Disease - Pipeline Review, H2 2013
- Parkinson's Disease - Pipeline Review, H2 2013
- Kidney Disease - Pipeline Review, H2 2013
- Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2013
- Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2013
- Huntington's Disease - Pipeline Review, H2 2013
- Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2013
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2013
- Fatty Liver Disease - Pipeline Review, H2 2013
- Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2013